Survival with Osimertinib plus Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC

Pasi A. Jänne

David Planchard

Kunihiko Kobayashi

Department of Respiratory Medicine, Saitama Medical University International Medical Center, Hidaka, Japan

James Chih-Hsin Yang

National Taiwan University Hospital, NTU Cancer Center, Taipei

Ying Liu

Natalia Valdiviezo

Department of Oncology, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru

Tae Min Kim

Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea

Liyan Jiang

Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai

Hiroshi Kagamu

Department of Respiratory Medicine, Saitama Medical University International Medical Center, Hidaka, Japan

Noriko Yanagitani

Department of Thoracic Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo

Jialei Wang

Department of Thoracic Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai

Bivas Biswas

Department of Medical Oncology, Tata Medical Center, Kolkata, India

Artem Poltoratskiy

Petrov Research Institute of Oncology, St. Petersburg, Russia

Yeni Neron

Oncology Research Center, Florianopolis, Brazil

Carlos Rojas

Bradford Hill Investigación Clínica, Santiago, Chile

Leona Koubkova

Department of Pulmonology, Motol University Hospital, Prague, Czech Republic

Carles Escriu

Department of Medical Oncology, Clatterbridge Cancer Centre National Health Service Foundation Trust, Liverpool, United Kingdom

Doreen A. Ezeife

Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

Helen Mann

Elena Armenteros-Monterroso

Oncology Research and Development, AstraZeneca, Barcelona

Yuri Rukazenkov

Oncology Research and Development, AstraZeneca, Cambridge, United Kingdom

Chee Khoon Lee

Department of Medical Oncology, Cancer Care Centre, St. George Hospital, Kogarah, NSW, Australia